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Deﬁnitive radiotherapy for unresected adenoid cystic carcinoma of the trachea
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Adenoid cystic carcinoma (ACC) is a rare malignancy that usually originates in the salivary glands of the head and neck but
has rarely been known to originate in the trachea. This tumor has a tendency for local and distant recurrences. The present
report describe a 66 years old female with unresectable ACC of the trachea who was treated with deﬁnitive radiotherapy (RT).
She presented humid cough and dyspnoea. A chest CAT scan and bronchoscopy were performed, showing a exophytic mass in
the in the middle third tracheal, occupying 85% of the tracheal lumen, with a diameter of 4 cm. Histological conﬁrmation was
obtained by biopsy. Endoprosthesiswas required. The patientwas treatedwith deﬁnitive three-dimensional conformal radiother-
apy (3DCRT), using photons and a dose of 60Gy. Esofagitis G1was appeared as acute toxicity and clinical and radiological response
were observed at 11 months after treatment. The surgical resection is the mainstay of treatment of tracheal adenoid cystic carci-
noma, tumor size, location, and patient comorbidities may preclude surgery, and the optimal nonsurgical management remains
undeﬁned. In the absence of locoregional lymph node metastases, the highly conformal radiotherapy is considered as alternative
treatment. The results of radiotherapy with photons for advanced ACC have been reported to be suboptimal in the setting of
inoperable, not completely resected and recurrent tumors. Nevertheless postoperative radiotherapy have been show to have a
favorable impact on local control rates and survival rates in advance stages of ACC: In our case we obtained a favourable clinical
and radiological response with acceptable toxicity performing deﬁnitive RT in unresectable tracheal adenoid cystic carcinoma.
http://dx.doi.org/10.1016/j.rpor.2013.03.305
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Introduction. The standard treatment in small cell lung cancer limited disease (SCLC LD) involves chemotherapy (CT) based in plat-
inum+ thoracic radiotherapy+prophylactic cranial irradiation (IPC). In patients <70 years with good ECOG, chemo-radiotherapy
treatment hyperfractionated (RTHF) concomitant early is considered the better treatment option for both local control and
long-term survival.
Objective. To analyze toxicity, response and survival in our series.
Material and methods. Patients diagnosed to SCLC LD between August’09 and June’12, treated with CT based in platinum+RTHF
concomitant according Turrisi scheme. Inclusion criteria were: <70 years, PS 0–1, good respiratory function, absence of signiﬁcant
comorbidity and socio-family support.
Results. We analyzed 12 patients (7 men and 5 women) with a median age of 62.5 years (range 43–73). Six patients received
concomitant QT-RTHF early on (with the ﬁrst 2 cycles), the other 6 was late. 45Gy were given 1.5Gy for session, two sessions
per day separated by 6–8h. No prophylactic nodal irradiation was performed. Patients received 4–6 cycles of chemotherapy and
then, except one patient who refused treatment, received IPC (36Gy at 2Gy per session). Both pulmonary and esophageal toxicity
was acceptable. Mean follow-up was 19.45 months (range 7–33 months). In 2 patients were lost follow-up, four have died of the
disease and 6 remain alive free of disease with a mean of 15.5 months (range 7–22).
Conclusions. QT-RTHF has shown better results in treating SCLC LD, although the long-term survival remains low (5–10%). 70% of
patients free of disease after 2 years do not fall, according to the literature. We will have to see the evolution of our patients.
http://dx.doi.org/10.1016/j.rpor.2013.03.306
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Introduction. Hypoxia is one of themain causes of the failure to achieve local control using radiotherapy. This is due to the increased
radioresistance of hypoxic cells. 18F-ﬂuoromisonidazole (18F-FMISO)-PET is a non-invasive imaging technique that can assist in
the identiﬁcation of intratumor regions of hypoxia. We initiated a phase I trial to examine the feasibility of 18F-FMISO PET/CT
guided IMRT with the goal of maximally escalating the dose to radioresistant hypoxic zones concurrent with chemotherapy in
stage III lung cancer patients.
Objective. This work investigates the feasibility of dose painting to these hypoxic regions in the patients included in the ﬁrst step
of dose escalation study.
Materials and methods. Four patients were included. The CT simulation, ﬂuorodeoxyglucose (18F-FDG) PET/CT, and18F-FMISO
PET/CT scans were co-registered using the same immobilization methods. A ﬁrst planning target volume (PTV-FDG) was deﬁned
by clinical examination and available imaging studies, including 18F-FDG PET/CT. Regions of elevated 18F-FMISO uptake within
